Equities research analysts forecast that ASLAN Pharmaceuticals Limited (NASDAQ:ASLN – Get Rating) will post earnings of ($0.17) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ASLAN Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.18). ASLAN Pharmaceuticals posted earnings per share of ($0.13) in the same quarter last year, which would indicate a negative year-over-year growth rate of 30.8%. The business is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that ASLAN Pharmaceuticals will report full-year earnings of ($0.59) per share for the current financial year, with EPS estimates ranging from ($0.79) to ($0.42). For the next financial year, analysts anticipate that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.41) to ($0.50). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Rating) last released its quarterly earnings results on Friday, March 25th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02).
Hedge funds have recently modified their holdings of the business. Barclays PLC boosted its holdings in ASLAN Pharmaceuticals by 169.6% in the 4th quarter. Barclays PLC now owns 508,964 shares of the company’s stock valued at $570,000 after purchasing an additional 320,200 shares during the period. Millennium Management LLC boosted its stake in shares of ASLAN Pharmaceuticals by 10.3% in the 4th quarter. Millennium Management LLC now owns 1,619,125 shares of the company’s stock valued at $1,813,000 after purchasing an additional 150,918 shares during the last quarter. Waterfront Wealth Inc. bought a new stake in shares of ASLAN Pharmaceuticals in the 4th quarter valued at about $302,000. GSA Capital Partners LLP bought a new position in ASLAN Pharmaceuticals during the fourth quarter worth about $89,000. Finally, Bank of America Corp DE bought a new position in ASLAN Pharmaceuticals during the 4th quarter worth about $216,000. 66.89% of the stock is currently owned by institutional investors.
Shares of ASLN stock opened at $0.84 on Friday. ASLAN Pharmaceuticals has a 1-year low of $0.73 and a 1-year high of $3.87. The stock has a 50 day simple moving average of $0.87 and a 200-day simple moving average of $1.21. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.75 and a quick ratio of 14.75. The company has a market cap of $31.91 million, a price-to-earnings ratio of -1.71 and a beta of 2.33.
ASLAN Pharmaceuticals Company Profile (Get Rating)
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and AhR Antagonist.
- Get a free copy of the StockNews.com research report on ASLAN Pharmaceuticals (ASLN)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Insiders Are Selling Palo Alto Networks
- Greenbrier Companies Stock has Green in its Future
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.